ACGT – Edward Netter Memorial Investigator Award in Cell and Gene Therapy for Pancreatic Cancer Research
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: inquire with unit
Memorial Deadline: Wednesday 29th, May 2024
External Deadline: Saturday 1st, June 2024
Description
With success in overcoming blood cancers using curative cell and gene therapies well established, Alliance for Cancer Gene Therapy’s current funding priority is focused on the most difficult-to-treat solid tumor cancers — including pancreatic cancer.
Pancreatic cancer is an aggressive disease that is predicted to become the second leading cause of cancer-related death worldwide by 2030. The overall 5-year survival rate is around 10%. Pancreatic cancer typically presents late with locally advanced or metastatic disease, and there are limited effective treatments available.
The ACGT – Edward Netter Memorial Investigator Award in Cell and Gene Therapy for Pancreatic Cancer Research prioritizes the advancement of cell and gene therapy research to improve outcomes for pancreatic patients.
The Award will provide an investment of $500,000 dollars toward high-impact research projects.
- Applicants are invited to submit a Letter of Intent, through proposalCentral, by June 1, 2024.
- For complete proposal submission details, please visit the ACGT website.
If you have any questions regarding the RFP, please contact:
Barbara Lavery, Chief Program Officer
Alliance for Cancer Gene Therapy
Blavery@acgtfoundation.org